PMID- 29046800
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 7
IP  - 4
DP  - 2017 Oct
TI  - Re-irradiation of locoregional esophageal cancer recurrence following definitive 
      chemoradiotherapy: A report of 6 cases.
PG  - 681-686
LID - 10.3892/mco.2017.1384 [doi]
AB  - There is currently no consensus on salvage therapy for recurrent esophageal 
      cancer. Salvage surgery is a well-established option for attaining long-term 
      survival; however, it is associated with a high risk of perioperative morbidity 
      and mortality. A total of 6 patients who underwent re-irradiation for recurrence 
      of locoregional esophageal cancer following definitive chemoradiotherapy were 
      investigated. The median interval between initial radiotherapy and re-irradiation 
      was 17.4 months (range, 6.4-59.2 months). Re-irradiation salvage therapy was 
      mostly administered with concurrent chemotherapy, which consisted of several 
      cycles of nedaplatin on day 1 and oral S-1 administration on days 1-14. The 
      median survival after re-irradiation was 13.6 months (range, 1.9-33.3 months). A 
      total of 3 patients who completed hyperfractionated radiation therapy survived 
      for >1 year. One patient has had no signs of recurrence or late radiation 
      toxicity for >2 years. Severe acute hematological adverse events (AEs) occurred 
      in 3 patients, including 1 case of grade 4 leukopenia. One severe late AE 
      occurred in 1 patient, who developed grade 3 dysphagia and became permanently 
      dependent on percutaneous endoscopic gastrostomy tube feeding. Salvage 
      radiotherapy is considered to be a good treatment option for inoperable 
      locoregional recurrent esophageal cancer. The results of the present study 
      demonstrated that re-irradiation, with or without chemotherapy, for recurrent 
      esophageal carcinoma after definitive chemoradiotherapy was tolerable and yielded 
      reasonably satisfactory results.
FAU - Katano, Atsuto
AU  - Katano A
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Yamashita, Hideomi
AU  - Yamashita H
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Nakagawa, Keiichi
AU  - Nakagawa K
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170818
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC5639416
OTO - NOTNLM
OT  - esophageal carcinoma
OT  - radiotherapy
OT  - recurrence
OT  - salvage therapy
OT  - squamous cell carcinoma
EDAT- 2017/10/20 06:00
MHDA- 2017/10/20 06:01
PMCR- 2017/08/18
CRDT- 2017/10/20 06:00
PHST- 2017/05/04 00:00 [received]
PHST- 2017/07/17 00:00 [accepted]
PHST- 2017/10/20 06:00 [entrez]
PHST- 2017/10/20 06:00 [pubmed]
PHST- 2017/10/20 06:01 [medline]
PHST- 2017/08/18 00:00 [pmc-release]
AID - MCO-0-0-1384 [pii]
AID - 10.3892/mco.2017.1384 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2017 Oct;7(4):681-686. doi: 10.3892/mco.2017.1384. Epub 2017 Aug 
      18.